11/8/2016 10:58:34 AM
Yisheng Biopharma, a Beijing vaccine company, will collaborate with San Diego's The Scripps Research Institute on a next-gen AIDS vaccine. Yisheng will contribute its PIKA vaccine adjuvant to a TSRI-developed vaccine consisting of novel gp140 trimers and self-assembling nanoparticles. TSRI scientists will also evaluate the potential of PIKA adjuvant for AIDS vaccine candidates. The PIKA adjuvant, a Toll-Like Receptor 3 (TLR3) agonist, has been tested in Phase I clinical trials for hepatitis B and Phase II trials for rabies, with promising results, according to Yisheng.
comments powered by